News Center

Ge Dian Renfu Medicine Assistant 2019 Staff Group Tour Successfully Concluded

The growth of employees is the growth of the enterprise, and the happiness of employees is the happiness of the enterprise. In order to strengthen the construction of corporate culture, reflect the company's humanized management, and implement the care of employees, let employees finish the busy work in the first half of the year, relax and enjoy the pleasant scenery of nature. With the support of the company's leaders, the company organized a trip to Guilin and Ningxia in batches during the company's annual production equipment shutdown and maintenance. Wandering between the smart and beautiful landscape, indulge in the vast desert oasis of enthusiasm. Through this collective activity, everyone not only enjoyed the beautiful scenery, relaxed their body and mind, and relieved the pressure brought by work and life.

11-18

Ge Dian Renfu Medicine Auxiliary Appears at 19th World Pharmaceutical Raw Materials China Exhibition (CPhI China 2019)

From June 18 to 20, 2019, the 19th World Pharmaceutical Raw Materials China Exhibition (CPhIChina2019) was grandly held in Shanghai New International Expo Center. As the weather vane of the international pharmaceutical industry, the CPhIChina covers all 17 pavilions of the New International Expo Center, creating the strongest lineup in history. The exhibition brought together more than 3200 outstanding domestic and foreign companies, including pavilions from South Korea, India, Poland, Turkey, Russia and other countries and more than 200 independent overseas exhibitors from the United States, Germany, France, Switzerland, Italy and other countries. Attracted from 120 countries and regions

11-18

Publicity: Ethyl paraben and butyl hydroxyphenyl ester CDE registration numbers have been publicized

Last week, the registration numbers of ethyl hydroxybenzoate and butyl hydroxybenzoate of Gedian Renfu Pharmaceutical Accessories Co., Ltd. were publicized on the CDE raw and auxiliary package registration platform. With the public announcement of the registration numbers of ethylparaben and butylparaben, Hubei Gedian Renfu Pharmaceutical Accessories Co., Ltd. is also the first pharmaceutical accessories enterprise in the country with 4 product registrations of ethylparaben. With the joint efforts of the company's research and development department and registration department, we have completed the process of research and development, pilot scale-up, stability inspection, registration data writing, etc. Now these four products have been publicized on the CDE raw and auxiliary package registration platform, with many closing points.

11-18

Opportunities and Challenges of "the belt and road initiative" Emerging Pharmaceutical Market

As we all know, China has become the world's second largest biomedical market. However, in recent years, under the influence of a series of policies such as consistency evaluation and volume procurement, the domestic pharmaceutical market environment has changed dramatically, and international development has become an important starting point to promote the structural adjustment of China's pharmaceutical industry and the transformation and upgrading of pharmaceutical enterprises. In the process of internationalization, on the one hand, the growth rate of the pharmaceutical market in developed countries and regions such as Europe and the United States has slowed down, the requirements of technical regulations are strict, and it is more difficult to enter; on the other hand, the potential of emerging markets is huge. According to statistics, 80% of the future growth in drug sales will come from emerging markets. By 2022, emerging markets will account for the global drug market.

11-04

GMP certification canceled the latest news announced

In the future, supervision and inspection records will become proof of compliance with GMP requirements, because the law requires the disclosure of all regulatory results, and each enterprise, the result of each inspection, is proof of GMP compliance. Recently, the industry authorities in an interview with Cyber Blue said: the cancellation of GMP/GSP certification is not new, as early as a few years ago began. In the future, supervision and inspection records will become proof of compliance with GMP requirements, because the law requires the disclosure of all regulatory results, and each enterprise, the result of each inspection, is proof of GMP compliance.

11-01

Well-known pharmaceutical companies have made efforts to high-end generic drugs, new drugs, high gross profit will continue.

A movie "I am not a drug god" adapted from the real purchasing of life-saving drugs brought the word "generic drugs" into people's vision. The so-called generic drugs, that is, after the end of the patent protection period of patented drugs, do not have the patent of the pharmaceutical companies imitation of alternative drugs. Generic drugs have the same therapeutic effect as the original drugs. At the same time, due to the relatively low price, generic drugs have become the choice for patients to reduce the burden of medicine. On October 9, the National Health Commission issued the "Notice on Printing and Distributing the First Batch of Encourage Imitation of Drugs". The catalog includes 33 drugs including anti-cancer drugs, rare disease drugs and immune system treatment drugs. Almost at the same time, drugs

10-23